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THE encouraging results of massive vitamin B12 dosage in treating neuro-
blastoma in children (Bodian, 1959) suggested a parallel investigation of the
effects of this vitamin on tumours occurring in experimental animals. Initial
attempts to implant tissue from human neuroblastomata were unsuccessful, and
therefore a spontaneous retroperitoneal tumour of mice was obtained (C1300,
Roscoe B. Jackson Memorial Laboratory, Bar Harbour, Maine). This was
originally considered to be a neuroblastoma, and although it has been shown
histologically to be an undifferentiated sarcoma, it was decided to test the effects
of vitamin B12 upon it, together with a fibrosarcoma of rats (PWA2) to broaden
the scope of the study.
If vitamin B12 did affect tumour tissue, it would be reasonable to expect a
relatively high uptake of the vitamin by such cells. The distribution of vitamin
B12 in neoplastic and other tissues has therefore been observed in mice and rats
bearing tumour transplants. As far as can be ascertained the only workers who
have reported studies of the relationship of vitamin B12 to tumour growth are
Oleson and Little (1949), Day, Payne and Dinning (1950), Miller et al. (1952),
Woolley (1955), Bennett, Ramsey and Donnelly (1956), Miller et al. (1956),
Georgadze (1960), Cooper and Paranchych (1961), and Nelson and Doctor (1962).
MATERIALS AND METHODS
The mice used in this investigation were of CAFI/JAX strain, obtained from
the Jackson Memorial Laboratory, which was also the source of the tumour with
which they were inoculated. The rats were ofthe August strain and were supplied
by the Chester Beatty Research Institute together with the fibrosarcoma (PWA2)
used for transplantation in these animals. Mice were fed on standard cubes
(Diet 41) and rats similarly (Diet 86).
The basic method pursued has been to take tissue from a tumour in one
animal and to inoculate this into a number of other hosts, allowing these trans-
plants to grow and repeating the transplantation to further hosts at regular
intervals. In each successive group of animals, all affected with the tumour, half
received vitamin B12 and half acted as untreated controls.
In studying the behaviour ofthe murine tumour under such conditions, mature
mice about 20 grammes in weight were inoculated in batches of 20 (all of the
same sex-male or female-in each batch) at a single session. The inoculant was
prepared by dissecting out a tumour from an affected animal, placing this in anVITAMIN B12 AND ANIMAL TUMOUR SYSTEMS
aqueous solution of penicillin and streptomycin, and removing from it 10 ap-
proximately equal samples for subcutaneous injection through a 14 S.W.G. Bash-
ford needle into separate mice. It must be emphasised at this point that the
tumours transplanted through control and vitamin-treated series of animals were
kept strictly separate. Control mice thus always received tumour transplants
from a control animal in the previous batch, and similarly in the case of treated
animals. This segregation was essential because the tumour used displayed such
a rapid rate of growth in mice that it was impracticable to keep the affected
individuals alive and under treatment for more than 10 days. Thus the long-
term behaviour of treated and untreated tumour tissues could only be compared
by carrying them separately through repeated series of control and vitamin-
treated hosts.
On the day after transplantation mice in the vitamin-treated series received
their first daily dose, 5 ,tg. of cyanocobalamin, given subcutaneously. Eight such
doses were administered, a total of 40 ,tg. to each animal. On the tenth day the
whole batch of 10 treated and 10 untreated controls were killed and dissected.
It was almost always comparatively easy to dissect the tumours, and their indi-
vidual weights were noted. Control and vitamin-treated series have now been
carried in parallel through 100 transplant cycles, spread over a period of nearly
3 years.
The rat fibrosarcoma has been studied in a similar manner, in parallel series of
equal numbers of control and treated animals in each transplant cycle. Mature
rats of about 200 grammes weight and of the same sex in each batch were inocu-
lated with PWA2 fibrosarcoma by the same technique as used in mice, using a
6 S.W.G. needle. Because of the size of the latter, which required a skin incision,
and of the greater difficulty of handling the rats, intraperitoneal anaesthesia was
adopted. Initially, control and treated batches numbered 7 each in every trans-
plant cycle, but this number has been gradually increased to 10 in succeeding
cycles as stocks of rats improved. As in the case of mice the length of the trans-
plant cycle was dictated by the rate of growth of the tumour, which proved much
slower in the rat fibrosarcoma. It was found possible to keep rats alive for 5 to 7
weeks, during which period the treated animals received daily individual doses of
30 ,ug. of cyanocobalamin. At the end of each transplant cycle normal control
and treated rats were killed and dissected, like the mice, and the same data
recorded. Transplants have now been passed through 15 cycles, during a period
of about 2 years.
Radioactive vitamin technique
Radioactive vitamin B12 was used as the 58Co isotope for injection in tracer
doses into mice and rats to estimate distribution of the vitamin in various tissues,
including tumours. It is well to recognise that radioactivity is assessed in such
experiments, and that results give a measure of the amounts of cobalt isotope
present, not of vitamin B12. If these should be dissociated in a particular tissue,
results would be fallacious. Barbee and Johnson (1951) have shown that such
dissociation occurs in the gut after oral dosage in rats but they reported that
chromatograms suggested that the 60Co isotope was stored as vitamin B12 in the
kidney. Rosenblum et al. (1952) demonstrated that the radioactivity in urine
after parenteral doses of 60Co B12 was due to intact radiovitamin, and Adams
(1961) has recorded similar findings in man. Grasbeck et al. (1961) concluded
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from their experiments in rats that after parenteral doses levels of activity in
kidney, liver, spleen, and a number of other tissues could be taken as a measure
of the take-up of radiovitamin.
Supplies of58Co B12 were obtained from the Radiochemical Centre, Amersham,
having a specific activity of about 1 atc/I ,g. Since it has been shown that
radiovitamin B12 is unstable in solution (Smith, 1959), only fresh aqueous solu-
tions were used. Dosage was adjusted between the dictates ofcounting technique
and physiological levels; suitable doses were found to be 0 075 ,tg. for mice and
02 Ilg. for rats. Animals received a single subcutaneous dose and were killed in
batches of 10 at intervals of 4, 24, 48, 72 and 96 hours thereafter. Each batch
of 10 consisted of 5 normal and 5 tumour-inoculated animals.
The mouse neuroblastoma is a rapidly growing tumour and tends to ulcerate
early. It was therefore necessary to select animals for tracer injections at the
right period of tumour growth. This was most conveniently achieved by main-
taining an adequate stock oftransplanted animals, from which batches of 5 could
be taken for injection at the appropriate stage of tumour size. This difficulty
did not affect experiments on rats, because of the slower rate of growth of the
PWA2 fibrosarcoma.
Batches of 10 animals (5 tumour-transplanted, 5 normal controls) were taken
at the intervals noted above, and were anaesthetized, heparinized. and exsan-
guinated. Individuals in each batch were killed in the same order in which they
had been injected to keep survival intervals as uniform as possible. Each mouse
or rat was then carefully dissected to remove the tumour (except in the controls),
liver, kidneys, spleen, and brain (rats only), and a sample of blood was also
collected.
The radioactivity ofeach specimen from every animal was measured separately
in a well-type scintillation counter using a thallium-activated iodide crystal, each
organ giving a count of well above 10 times the background activity. Total
radioactivity injected into each animal was calculated from a count on a measured
specimen of the solution used.
Microbiological assay
For microbiological assay the tumours, livers, kidneys, spleens, and brains
were dissected from mice and rats and stored at -10° C., the animals being taken
from the main experimental series. From each transplant group assayed the
above organs were separately pooled, so that there were 5 pools from the vitamin-
treated animals and 5 from the batch controls. Each tissue pool was chopped up
and extracted in a buffered (pH 4.8) cyanide-activated papain solution in the
ratio of 1 to 20 by volume. The vitamin B12 activity of diluted samples of the
supernatant extract was assessed by the growth of Lactobacillus leichmannii 313
(ATCC7830), using Dano-B12 assay medium, after the method described by
Spray (1955) and Matthews (1962).
Spray and Taylor (1958) have shown that, using Lactobacillus, 50 per cent of
vitamin B12 activity is alkali-stable in rat serum, though the fraction in liver
tissue was less than 3 per cent. In agreement with this our assays demonstrated
a similar low alkali-stable activity in liver and also in the other tissues involved in
this study. This fraction was therefore ignored.
Vitamin B12 activity of the sample tissue extracts was estimated by photo-
electric comparison of the density of bacillus growth in these and in standard
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solutions of the vitamin, after incubation for 20 hours at 370 C. in a uniformlv
illuminated waterbath. It was found that the stock of test organism could be
most conveniently maintained in a gelatin base medium, which produced dis-
persed cultures easier for sampling.
RESULTS
1. Effects of Massive Dosage of Vitamin B12
(a) C1300 mouse neurob7astoma in CAFI/JAX strain mice
The effects of prolonged massive dosage of vitamin B12 on the murine tumour
have been followed continuously by serial transplantation since August, 1959.
To date 100 successive batches have been carried through, together with equal
numbers of animals which were tumour-inoculated but received no vitamin, thus
acting as controls. Initially the mice receiving vitamin B12 showed an increase
in average tumour weight when compared with the control animals; but an
opposite effect soon supervened. This diminution in growth of transplants has
persisted in vitamin-treated mice ; and while there have been slight vagaries
from this trend in individual mice, the overall pattern in the last 88 transplant
cycles has shown an average diminution of 23 per cent.
A second and identical tumour transplant series was started later than the
above experiment, using a fresh sample of the same tumour. It was carried on
in parallel through a further 32 transplantations. At this juncture, about a
year after the commencement of this series, the tumour became extinct in the
treated mice. At 10 months, shortly before the tumour became extinct, it
showed a growth diminution of 60 per cent in the vitamin-treated animals, com-
pared with the controls.
(b) PWA2 fibrosarcoma in August strain rats
Long term experiments similar to the above have also been carried out in
rats to study the effects of massive vitamin B12 dosage on a different tumour, the
PWA2 fibrosarcoma. Because of its slower growth rats must be kept alive much
longer, and only 15 successive transplants have been carried through in a period
of 2 years. Some variation in the behaviour of the tumours in the vitamin-
treated rats has occurred, as is also true ofthe control animals; but in the treated
animals, taken as a whole, there has been on average a threefold increase in the
weight of tumours, compared with controls.
2. Relative Uptake of Vitamin B12
(a) Distribution ofradioactivity after single small injections ofcobalt-labelled vitamin
B12 (58Co B12)
The distribution of radioactivity in certain tissues, including tumours, after
tracer doses of vitamin B12 is shown in Tables I to IV. Both mice and rats were
studied in groups of 5, with an equal number of normal animals. In both series
of experiments 5 groups of animals (5 tumour-bearing and 5 normals in each)
were killed at intervals of 4 to 96 hours, as the tables show. As will be evident,
the distribution of radioactivity in tumours, liver, spleen, brain, and blood has
been expressed in both relative and absolute terms. In Tables I and II the
results are shown as percentages of the total injected dose, compared on the basis
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TABLE I.-Distribution of Radioactivity after Tracer Doses of 58CO Vitamin B12
Average percentage of injected dose present in 1 gramme of wet tissue
Time in hours
- A_ I
24 48
Tumour-bearing series of mice
3-6 4-4 8-3
2-1-5-2 2-5-9-0 4-7-10-1
12-2 12-9 14-5
9-9-14-3 9-8-15-4 10-9-17-4
10-1 7-5 4-7
7-0-15-3 6-2-10-0 3 9-5-2
0-6 0-7 0-6
0-4-0-9 0-6-0-7 0-5-0-8
5-6 5-3 3-5
3-3-9-4 4-2-6-2 1-6-5-7
Control series of mice
12-9 15-6 15-3
12-0-14-1 14-8-16-1 13-2-17-4
11-0 6-3 6-8
8-2-17-2 6-1-6-4 5-3-11-7
0-6 0-8 0-7
0-5-0-8 0-6-1-2 0 7-0-8
9-2 5-6 2-9
7-7-13-0 4-0-8-9 2-4-3-2
72
2-9
2-3-3-6
17-6
14-7-21-6
4-8
4-05-5
0-8
0-6-1-3
2-6
2 0-3-6
17-0
15-4-18- 8
5-5
4-1-6-7
0-8
0-6-1-3
3-1
1-2-4 4
96
9-0
3-4-15-5
15-4
11-8-17-3
4- 1
2-8-5- 7
0-7
0-5-0-9
2-2
1-4-3-4
19-2
17-3-21-2
6-3
6-1-6-5
0-6
0-1-1-0
1-9
1-2-2-3
Each mouse received 0- 075 jug.
TABLE II.-Distribution of Radioactivity after Tracer Doses of 58Co Vitamin B12
Average percentage of injected dose present in whole organs
Time in hours
4 24 48
Tumour-bearing series of rats
1-20 0-26 0-83
0-6-1-8 0-1-0-4 0-005-3-1
4-18 3-26 4-16
4 0-4-3 2 7-3-6 3-6-4-8
16-88 18-74 17-66
16-1-18-4 16-0 20-9 15-6-19-8
1-50 0-76 0-74
1-3-1-7 0-7-0-8 0-6-0-8
1-56 0-50 0-44
1-0-2-0 0-4-0-6 0 3-0-8
3-92
3 8-4-3
15-24
14-2-16-6
1-38
1 -2-1-6
0-96
0-8-1-1
Control series of rats
4-00
3-6-4-2 2-
22-12 1
19-6-25-2 10-
0-84
0-6-1-3 0-
0-64
0-2-0-8 0-
4-06
*6-4-6
18-84
*8-23-6
0-66
*4-1-0
0-54
3-0-8
72 96
0-94
0-6-1-4
4-16
3-9-4-8
17-88
15-9-20-0
0-68
0 6-0-8
0-32
0-2-0-5
5-10
4 8-5-6
17-86
14- 7-19-3
0-90
0-7-1-1
0-60
0-3-1-0
0-60
0 3-0-7
4-44
3-7-4- 8
17-74
14-9-20-2
0-80
0-6-1-0
0-44
0 1-0 6
5-38
5-1-5-6
21-94
19-3-25-5
0-54
0-4-0- 8
0-48
0 3-0-6
Each rat received 0-2 I4g. Batches of five animals killed at the above intervals of time.
Tumour
Range
Liver
Range
Kidneys -
Range
Spleen
Range
Blood (total)
Range
Liver
Range
Kidneys
Range
Spleen
Range
Blood (total)
Range
Tumour
Range
Liver
Range
Kidneys
Range
Spleen
Range
Blood (total)
Range
Liver
Range
Kidneys -
Range
Spleen
Range
Blood (total)
Range
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TABLE III.-Distribution ofRadioactivity after Tracer Doses of 58Co Vitamin B12
Average percentage of injected dose present in 1 gramme of wet tissue
Time in hours
4 24 48 72 96
Tumour-bearing series of mice
Tumour . . 10-7 17-0 14-6 13-2 12-8
Range . . . 7-4-15-3 14-1-21-4 10-9-18-1 7 3-18-1 10-0-15-9
Liver . . . 12-0 13-0 15-7 15-8 14-8
Range . . . 10-2-14-6 10-6-15-4 11-4-23-2 11-8-196 10-8-17-9
Kidney8 . . 39-7 31-7 19-6 18-6 17-0
Range . 29-0-58-6 24-2-45-6 17-1-23-5 15-0-23-1 10-4-23-0
Spleen . . 4 7 57 5-4 6-4 51
Range . . 33-5-7 5-1-63 4-8-6-2 5-2-9-8 4-2-6-5
Blood (total) . . 5-6 5-3 3-5 2-6 2-2
Range . 3-3-9-4 4-2-6-2 16-5-7 2 0-3-6 1-4-3-4
Control series of mice
Liver . . . 13-1 16-0 15-0 18-8 14-9
Range . 11-7-14-4 14-2-17-7 12-6-16-8 16-7-20-9 14-5-15-6
Kidneys . . 53-4 26-6 26-5 24-3 16-0
Range . . . 34-1-101 22 1-33-6 17-6-50-7 20-0-28- 1 14-7-18-0
Spleen . . 4-6 6-1 5-4 5-8 4- 1
Range . 4-0-5-0 4-9-7-1 4-3-6-6 5-0-7-2 1-0-7-2
Blood (total)
Range . . 7-7-13-0 4-0-8-9 2-4-3-2 1-2-4-4 1-2-2-3
Each mouse received 0- 075 pug. Batches of five animals killed at varying intervals of time.
TABLE IV.-Distribution of Radioactivity after Tracer Doses of 58Co Vitamin B12
Average percentage ofinjected dose present in 1 gramme of wet tissue
Time in hours
4 24 48 72 96
Tumour-bearing series of rats
Tumour 0-94 0-76 0-82 0-60 0-48
Range 0-7-1-1 0-6-09 0-2-2-3 0-4-1-0 0-3-0-6
Liver . . 0-34 0-42 0-54 0-48 0-38
Range 0-3-0-4 0-3-0-6 0-4-0-7 0-4-0- 5 0-3-0-4
Kidney8 . . 7-9 9-24 8-48 8-42 8-32
Range . . 6-1-9-3 7-2-10-2 7-1-10-2 7-4-11-7 7-3-9-3
Spleen . . . 1-48 0-96 0-84 0-76 0-66
Range . . . 1-4-1-6 09 1-1 0 7-0-9 0-7-0-9 0-6-0- 7
Blood (total) . 1-56 050 0-44 0-32 0-44
Range . . . 1 0-2-0 0-4-0-6 0-3-0-8 0-2-0-5 0-1-0-6
Control series of rats
Liver 0-4 0-36 0-46 0-52 0-54
Range . . 0-3-0-5 0-4-0-6 0-5-0-6 05-0-6
Kidney8 . . 7-82 11-34 8-68 7-9 10-2
Range . 7 3-8-5 8-9-14-7 6- 1-11-3 6-2-8-8 9-3-11-0
Spleen . . 1-66 0-98 0-80 0-68 0-76
Range . . 1-5-1-8 0-6-1-3 0-6-1-1 0-5-0-8 0-6-0-9
Blood (total) 0-96 0-64 0-54 0-60 0-48
Range . 0-8-1-1 0-2-0-8 0-3-0-8 0-3-1-0 0-3-0-6
Each rat received 0-2 ,ug. Batches of five animals killed at above intervals of time.
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of counts in unit time; they thus express the amounts found in whole organs.
Results set out in this way do not permit direct comparison of the concentrations
in individual tissues. This comparison can only be made by calculating the per-
centages of injected counts taken up by unit mass of the different tissues, as has
been done for Tables III and IV.
Regarding the organs selected for examination, the liver is the storage organ
in the mouse (Miller et al., 1956) and the kidney in the rat (Okuda, 1962). Since
the kidney is an excretory organ with respect to vitamin B12 in both species, high
concentrations are to be expected in both these organs, in experiments on a short
time basis. Originally a considerable variety of other organs was examined, and
the spleen was chosen from these as a convenient representative of those showing
relatively low radioactivity. Blood concentration was a necessary consideration
because it was not practicable to assess the radioactivity of an organ separately
from its blood content. -t
As will be at once apparent from the tables of results the murine tum'our
showed concentrations much higher than were found in the spleen. Tumour
radioactivity reached a maximum in the first 24 hours after injection, showing
thereafter a gentle fall. This descent might be due to excretion of the vitamin;
but since over the period covered by the experiments the blood concentrations
displayed only a slow fall, it is more likely that the diminution in tumour radio-
activity reflected its rapid growth-perhaps in conjunction with a falling blood
level. Despite this, the tumours showed, at 96 hours after tracer injection,
levels of radioactivity not far short of those in the liver.
In contrast to the mouse neoplasm, the fibrosarcoma investigated in rats
showed no outstanding concentrations in comparison with other tissues. In
comparing the two series of experiments, however, two difficulties must be
pointed out. Firstly, the rats received a proportionately smaller dose of radio-
vitamin (approximately one quarter of the dose given to mice). Secondly, the
liver does not act as a storage organ in the rat. For both these resons the levels
of radioactivity in rat livers were much lower than in mice. Since the kidney is
both a storage and an excretory organ in the rat, it also affords no simple com-
parison. It will nevertheless be noted that in rats the tumour concentrations of
vitamin B12 activity were no more than levels found in their spleens.
(b) Distributions of vitamin B12 activity after massive and prolonged dosage as
estimated by microbiological assay
In order to examine the distribution of vitamin B12 activity following high
and prolonged dosage, groups of rats and mice were taken from the main experi-
mental series of the investigation. Five batches of rats and 10 of mice were
studied, together with equal numbers of untreated animals as controls. It is to
be noted that in these series the control animals had received tumour transplants.
The results of these experiments are shown in Table V. The kidneys, of
course, show very large increases in vitamin B12 activity in both species, indicative
ofexcretion. Liver levels were much raised in mice but not in rats, corroborating
existing views of this organ's different roles in the two animals in relation to
vitamin B12 storage. This difference is all the more noteworthy in consideration
of the fact that the rats lived four to five times as long as the mice. Since daily
vitamin dosage was in these experiments approximately proportionate to body
weight, the rats received several times more vitamin than the mice, and their
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TABLE V.-Distribution of Vitamin B12 Activity after Repeated High Doses
Average vitamin B12 activity measured in tumg. per gramme of wet tissue
Mice. Each mouse in the treated series received 5 ug.
cyanocobalamin daily for 8 days; batches (10 mice) were killed
on the tenth day.
Increase
Control Treated (%)
Tumour . . 138 . 262
Range . . . 95-220 . 125-562 . 90
Liver . . 382 . 610
Range . . 245-500 . 400-880 . 60
Kidney . 330 7,085
Range . . 240-425 . 4,500-10,000
Spleen . . . 323 . 373
Range . . 225-550 . 275-510 . 15
Brain . . . 77 . 91
Range . . 65-95 . 80-110 . 18
Rat8. Each rat in the treated series received 30 jug. cyano-
cobalamin daily for 6 to 7 weeks; batches (10 rats) wore killed.
Incroase
Control Treated (%)
Tumour . . 111 . 172
Range . . 65-170 100-250 . 55
Liver . . 192 . 222
Range . . 88-192 . 125-300 . 15
Kidney . 930 . 12,750
Range . . 326-1,500 7,000-20,000
Spleen . 248 . 334
Range . . . 128-325 . 160-437 . 29
Brain . . . 100 . 138
Range . 65-170 . 66-250 . 38
tissues might be expected to show higher levels. In the case of the spleen and
the brain this was indeed so, whereas the reverse obtained in the two tumours.
It will be seen that the murine tumour showed an average increase of 90 per cent
in vitamin B12 activity, compared with an increase of 55 per cent in the rat fibro-
sarcoma, despite the much more prolonged dosage given to rats. However, this
difference in dosage should not, perhaps, be unduly stressed, in view of the aug-
mented excretion of vitamin B12 which accompanies high dosage. Nevertheless,
it is clear from the results of these experiments that while the mouse tumour
showed an increase of vitamin B12 activity five or six times greater than occurred
in the brain or spleen, the increase in the rat fibrosarcoma was no more than
doubled in comparison with the same two organs.
DISCUSSION
The original concept which led to clinical trials of vitamin B12 in human cases
of neuroblastoma, namely that the maturation effect of this vitamin on haemo-
poietic tissue might also apply to embryonic tumour cells, was only occasionally
supported by the results (Bodian, 1959). Yet marked changes did occur. Instead
of the expected maturation of neuroblasts into ganglion cells, there appeared to
be an actual regression in the size of about 50 per cent of the human neuro-CAROLYN C. RIGBY AND MARTIN BODIAN
blastomata treated. In the animal experiments prompted by these clinical
results and reported here, the effects have been somewhat different. In the
mouse series an inhibition of tumour growth has been observed. Whether re-
gressive effects would have occurred in individual mouse tumours it is impossible
to say, their rate of growth being such as to preclude dosage for the periods of
time possible in the human neuroblastoma. In the two main series of mice in
which the effects of vitamin B12 on transmitted C1300 tumours have been studied
neoplastic growth has been markedly depressed-to the extent of 23 and 60 per
cent in the two series. In the latter one the transplanted tumour eventually
succumbed. It is not easy to account for the difference in degree of inhibition
in these two series, for the mice in both were derived from the same strain and the
experiments were identical in technique, apart from one particular.
The behaviour of the rat fibrosarcoma resembled that ofthe murine tumour in
the latter's initial phase ofgrowth augmentation, but in the rat series this stimula-
tion of growth has persisted through 15 transplant cycles, and has also been more
pronounced than was observed in the early stages of the mouse tumour trans-
plants. It is apposite to mention here the early findings of Oleson and Little
(1949), who recorded a similar response in Rous sarcoma growth in chicks. Un-
fortunately they published no metrical data, but merely stated that tumour
growth was most noticeably enhanced when vitamin B12 dosage was combined
with pteroylglutamic acid.
The difference in response of the two tumours so far studied in our experi-
ments presumably indicates a selective action on the part of vitamin B12. It
might be objected that the rat fibrosarcoma has been carried through a much
smaller number of serial transplantations (15) than the mouse tumour (100).
However, the rats lived much longer, so that these numerically very different
series in fact occupied comparable lengths of time (2 and 3 years respectively).
Such simple comparisons between two different neoplasms in separate series are
perhaps unlikely to yield much concrete information. More illuminating are the
results of uptake studies.
As has been demonstrated, uptake of vitamin B12 was markedly greater in the
murine tumour, whether shown by single tracer dose technique or by micro-
biological assay after massive dosage. With the tracer technique the difference
in uptake between unit weights ofthe mouse and rat tumours was in the ratio of
1 to 17-6, and approximately 1 to 2 after massive dosage. Miller et al. (1956) have
found uptake of the same order in Sprague-Dawley rats using a Walker carcino-
sarcoma. They considered that the relative uptake by this neoplasm indicated
that vitamin B12 was important in the growth of the tumour. Cooper and
Paranchych (1961) have observed the specific uptake of vitamin B12 in vitro by
Erlich ascites tumour cells and HeLa cells. Both groups of workers held the
view that the vitamin is in some way involved in the growth of some neoplasms,
but they gave no indication that it actively augmented the rate ofenlargement in
their experiments. Day et al. (1950), Miller et al. (1952), and Georgadze (1960)
have all recorded evidence of enhancement of the activity of carcinogens by
vitamin B12. On the contrary inhibition of carcinogenetic effect by vitamin
B12 has been recorded by Bennett et al. (1956). So far no other investigators
appear to have observed retardation of the growth of transplanted tumours by
vitamin B12. It seems likely, therefore, that neoplasms may vary in their type
of response to this vitamin, as has been our experience so far. However that
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may be, the C1300 tumour studied in this investigation showed not only a clearly
marked diminution in growth rate in a prolonged series of transplant experiments
under vitamin B12 dosage but also a high specific uptake of this agent.
SUMMARY
The effects of massive vitamin B12 dosage on serially transplanted tumours
were studied in August strain rats (15 series in 2 years, PWA2 fibrosarcoma) and
CAFI/JAX mice (100 series in 3 years, 32 series in one year, C1300 neuroblastoma).
The vitamin treated rats' tumour growth was increased by 200 per cent, and
tumour vitamin content by 55 per cent, whereas in mice corresponding figures
were a decrease of 23 per cent in growth (in the shorter series the tumour became
extinct after one year) and an increase of 90 per cent in vitamin content.
Estimates of the affinity of the two tumours for vitamin B12 using tracer
technique showed concentrations in mouse tumours on average 17 6 times that in
rat tumours.
These results are interpreted as indicating a selective action of vitamin B12
and are discussed in relation to other findings.
We wish to record our indebtedness to Dr. Sephton Smith and Mr. R. Innes
for much helpful advice, and to Messrs. Ralph Addison, Michael Bland and Peter
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Cancer Campaign mediated through the Tumour Committee of this hospital.
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